Rafael Holdings, Inc.RFL

時価総額

PER

臨床・前臨床の医薬品企業への投資持株会社の有力企業。希少疾患向け治療候補やリポソーム医薬などパイプラインを展開。2024年1月の子会社買収、2024年3月の主要持分再編、2024年8月21日の臨床会社との合併協定。米国、イスラエル、欧州を中心に展開。

概要財務

サマリーテーブルに戻る

	2018年 7月31日	2019年 7月31日	2020年 7月31日	2021年 7月31日	2022年 7月31日	2023年 7月31日	2024年 7月31日
Consolidated net loss	-12	-5	-11	-	-142	-2	-65
Less: Income from discontinued operations	-	-	-	-	2	-	-
Consolidated net loss from continuing operations	-	-	-	-	-141	-9	-65
Depreciation and amortization	2	2	2	1	0	0	0
Gain on sale of property and equipment	-	-	-	-	-	-	0
Unrealized gain on investment - Hedge Funds	-	-	-	-	-	-	0
Unrealized gain on investment in equity securities	-	-	-	-	-	0	-
Realized loss on investment in equity securities	0	0	-	-	-	-	-0
Realized gain on available-for-sale securities	-	-	-	-	-	0	2
Amortization of discount on available-for-sale securities	-	0	0	0	0	-	-2
Loss on initial investment in Day Three upon acquisition	-	-	-	-	-	-	2
Realized gain in equity investments - Cyclo	-	-	-	-	-	-	0
Unrealized gain in equity investments - Cyclo	-	-	-	-	-	-	-0
Unrealized gain on convertible notes receivable, due from Cyclo	-	-	-	-	-	-	1
Recovery of receivables from Cornerstone	-	-	-	-	-	-	-31
In-process research and development expense	-	-	-	-	-	-	90
Gain on dissolution of a business	-	-	-	-	-	-	0
Equity in loss of Day Three	-	-	-	-	-	-	0
Bad debt expense	-	-	-	-	-	-	0
Stock-based compensation	-	-	-	7	-1	2	2
Trade accounts receivable	-	-	-	-	-0	0	0
Interest receivable	-	-	-	-	0	0	0
Prepaid expenses and other current assets	0	0	-0	1	4	-0	-1
Other assets	1	-0	0	-0	-0	0	-0
Accounts payable and accrued expenses	-0	1	1	0	0	-1	-0
Other current liabilities	-0	0	0	0	4	1	-1
Due to related parties	-	-	-0	-	-	-0	0
Other liabilities	-	-	-	-	-	0	-0
Net cash used in continuing operations	-	-	-	-	-26	-10	-8
Net cash used in discontinued operations	-	-	-	-	-0	-1	-
Net cash used in operating activities	-2	-3	-5	-16	-26	-11	-8
Purchase of property and equipment	1	0	1	0	-	-	0
Purchases of available-for-sale securities	-	-	-	-	-	-	156
Proceeds from the sale and maturities of available-for-sale securities	-	-	-	-	-	185	153
Proceeds from Day Three patent sale	-	-	-	4	-	-	0
Purchase of intangible assets	-	-	-	-	-	-	0
Proceeds from sales of equity securities	-	-	-	-	-	-	0
Issuance of Convertible Notes, Due from Cyclo	-	-	-	-	-	-	-4
Purchase of Investment in Day Three	-	56	-	-	-	-	-
Purchase of Investment in Cyclo	-	-	-	-	-	-	7
Issuance of convertible note receivable	-	-	-	-	-	-	1
Issuance of Day Three Promissory Notes	-	-	-	-	-	2	2
Proceeds from investments - Other Pharmaceuticals	-	-	-	-	-	-	0
Purchases of equity securities	-	-	-	-	-	2	-
Cash acquired in acquisition of Day Three, net of cash payments	-	-	-	-	-	-	-1
Cash acquired in the Cornerstone Acquisition, net of cash payments	-	-	-	-	-	-	-1
Proceeds from hedge funds	-	-	-	-	-	-	3
Net cash used in investing activities of continuing operations	-	-	-	-	-64	-27	-11
Payment of transaction costs for sale of 520 Property - discontinued operations	-	-	-	-	2	-	-
Net cash provided by investing activities of discontinued operations	-	-	-	-	-0	48	-
Net cash (used in) provided by investing activities	4	-31	-1	-8	-64	21	-11
Principal payments on installment note payable	-	-	-	-	-	-	1
Payments for taxes related to shares withheld for employee taxes	-	-	-0	-	-	0	0
Purchases of treasury stock	-	-	-	-	-	-	0
Proceeds from sale of Rafael Medical Devices membership units	-	-	-	-	-	-	1
Net cash used in financing activities of continuing operations	-	-	-	-	104	-0	-0
Net cash used in financing activities of discontinued operations	-	-	-	-	-	-15	-
Net cash used in financing activities	2	31	-0	30	104	-15	-0
Effect of exchange rate changes on cash and cash equivalents	-	-	-	-	-0	-0	-0
Net decrease in cash and cash equivalents	-	-	-	-	14	-5	-19
Acquisition of additional ownership interest in LipoMedix	-	-	-	-	0	0	-
Conversion of RFL Line of Credit into Cornerstone Common Stock	-	-	-	-	-	-	38
Conversion of 2023 Promissory Note into Cornerstone Common Stock	-	-	-	-	-	-	3
Recognition of noncontrolling interest in the Cornerstone Acquisition	-	-	-	-	-	-	28
Recognition of noncontrolling interest in the RP Finance Consolidation, net of elimination	-	-	-	-	-	-	10
Gain on RP Finance Consolidation recorded as an adjustment to additional paid-in capital due to related party nature of transaction, net of elimination	-	-	-	-	-	-	6
Noncash consideration received in exchange for equipment	-	-	-	-	-	-	0
Elimination of principal and accrued interest on the Day Three Promissory Notes included in consideration for acquisition of Day Three	-	-	-	-	-	-	2